ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer Patients

Dawn L. Hershman, MD
Published: Tuesday, Jun 23, 2015



Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) comapred to continuous ADT in prostate cancer.

The study looked at multiple late effects across both groups, including ischemic and thrombotic events, bone fractures, diabetes, obesity, depression, dementia, and sexual dysfunction.

There was a statistically significant higher rate of ischemic and thrombotic late effects among patients who had received intermittent ADT compared to continuous ADT. Other types of late effects were for the most part similar across the two groups, says Hershman.

These findings suggest more research is needed on the late effects of intermittent ADM before it should be commonly utilized, says Hershman.
 


Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) comapred to continuous ADT in prostate cancer.

The study looked at multiple late effects across both groups, including ischemic and thrombotic events, bone fractures, diabetes, obesity, depression, dementia, and sexual dysfunction.

There was a statistically significant higher rate of ischemic and thrombotic late effects among patients who had received intermittent ADT compared to continuous ADT. Other types of late effects were for the most part similar across the two groups, says Hershman.

These findings suggest more research is needed on the late effects of intermittent ADM before it should be commonly utilized, says Hershman.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x